利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

37 条记录 (耗时 0.022 秒)

    Microcapsules with modified release of active principles with low solubility for oral delivery
    31.
    发明申请
    Microcapsules with modified release of active principles with low solubility for oral delivery 审中-公开
    具有改进释放活性成分的微胶囊，具有低溶解性用于口服递送

    公开(公告)号：US20060275376A1

    公开(公告)日：2006-12-07

    申请号：US10522234

    申请日：2003-07-28

    申请人： Florence Guimberteau ,  Catherine Castan ,  Remi Meyrueix ,  Gerard Soula

    发明人： Florence Guimberteau ,  Catherine Castan ,  Remi Meyrueix ,  Gerard Soula

    IPC分类号： A61K9/50 ,  A61K9/16

    CPC分类号： A61K9/5015 ,  A61K9/5026 ,  A61K9/5047

    摘要： The invention concerns microcapsules for reliably modified release and adapted to industrial reproduction of an active principle hardly water-soluble, other than anti-hyperglycemia agents Each of said microcapsules comprises a core of hardly soluble active principle and a coating film applied on the core. Their mean diameter is less than 1000 microns. The coating film contains a film-forming polymer (P1) insoluble in gastrointestinal tract fluids, a water-soluble polymer (P2), a plasticizer (PL), and optionally a lubricating surfactant (TA). Said coating film represents at least 4% p/p of dry mraner of their total weight. and its components P1, P2. PL satisfy the following characteristics: dry weight mass fraction of PI relative to the total coating weight ranging between 40 and 90%; dry matter weight fraction of PL/P1+P2 ranging between 15 and 60%: dry matter weight fraction of PL/P1+P2 ranging between 1 and 30%. The invention also concerns the uses of said microcapsules in galenic formulation.

    摘要翻译： 本发明涉及用于可靠调节释放的微胶囊，并且适用于除抗高血糖剂以外的几乎不溶于水的活性成分的工业复制。所述微胶囊中的每一种都包含难溶的活性成分的核心和涂覆在芯上的涂膜。 它们的平均直径小于1000微米。 涂膜含有不溶于胃肠道液的成膜聚合物（P1），水溶性聚合物（P2），增塑剂（PL）和任选的润滑表面活性剂（TA）。 所述涂膜占其总重量的至少4％p / p干燥颗粒。 及其部件P1，P2。 PL满足以下特征：相对于总涂层重量的40重量％至90重量％的PI的干重质量分数; PL / P1 + P2的干物质重量分数在15和60％之间：PL / P1 + P2的干物质重量分数范围在1％和30％之间。 本发明还涉及所述微胶囊在盖仑制剂中的用途。

    Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
    33.
    发明申请
    Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s) 有权
    用于修饰释放活性成分的水性悬浮液形式的口服药物制剂

    公开(公告)号：US20060165807A1

    公开(公告)日：2006-07-27

    申请号：US10510643

    申请日：2003-04-07

    申请人： Catherine Castan ,  Florence Guimberteau ,  Remi Meyrueix

    发明人： Catherine Castan ,  Florence Guimberteau ,  Remi Meyrueix

    IPC分类号： A61K9/50 ,  A61K9/16

    CPC分类号： A61K9/5047 ,  A61K9/0053 ,  A61K9/0095 ,  A61K9/10 ,  A61K9/5015 ,  A61K9/5026 ,  A61K9/5042 ,  A61K31/155 ,  A61K31/192 ,  A61K31/43 ,  A61K31/522 ,  A61K31/585

    摘要： The invention concerns liquid pharmaceutical formulations, for oral delivery, with modified release of active principle(s) excluding amoxicillin and consisting of suspensions of coated particles of active principles (microcapsules). The microcapsules constituting the dispersed phase of the suspension are designed, according to the invention, to enable modified release of the active principle(s), in accordance with a profile which remains unaltered during the shelf life of the liquid suspension. Therefor, the invention consists in selecting a coating composition specific to the microcapsules consisting of at least four components enabling preservation of said microcapsules in water without altering their properties of modified release of the active principle, said liquid phase being furthermore saturated with active principle(s).

    摘要翻译： 本发明涉及用于口服递送的液体药物制剂，其具有除阿莫西林以外的活性成分的改进释放，并且由活性成分的包被颗粒（微胶囊）的悬浮液组成。 根据本发明，构成悬浮液分散相的微胶囊根据在液体悬浮体的保质期内保持不变的轮廓来实现活性成分的改性释放。 因此，本发明在于选择由至少四种组分组成的微胶囊特性的涂料组合物，所述组合物能够在水中保存所述微胶囊，而不改变其活性成分的改性释放性质，所述液相还用活性成分 ）。

    Carvedilol salts, anhydrates and/or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
    34.
    发明申请
    Carvedilol salts, anhydrates and/or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods 有权
    卡维地洛盐，其水合物和/或溶剂合物，相应的药物组合物，控制释放制剂和治疗或递送方法

    公开(公告)号：US20050196459A1

    公开(公告)日：2005-09-08

    申请号：US10996780

    申请日：2004-11-24

    申请人： Catherine Castan ,  Florence Guimberteau ,  Remi Meyrueix ,  Gerard Soula

    发明人： Catherine Castan ,  Florence Guimberteau ,  Remi Meyrueix ,  Gerard Soula

    IPC分类号： A61K20060101 ,  A61K9/16 ,  A61K9/22 ,  A61K9/50 ,  A61K31/403

    CPC分类号： A61K9/1635 ,  A61K9/1641 ,  A61K9/1658 ,  A61K9/2077 ,  A61K31/403

    摘要： The field of the invention is that of oral pharmaceutical medicinal products or compositions, more particularly of the type of those comprising one or more active principles. The aim of the invention is to provide an improved oral medicinal product that can be administered in one or more daily doses, with modified release of active principle (in particular an active principle), for improving the prophylactic and therapeutic efficacy of such a medicinal product. This aim is achieved by means of the multimicrocapsular oral pharmaceutical form according to the invention in which the release of the AP is controlled by means of a double mechanism of triggering the release: “time triggering” and “pH triggering”. This medicinal product comprises microcapsules with modified release of active principle, each containing a core comprising the active principle and one or more swelling agents, and at least one coating making possible the modified release of the active principle.

    摘要翻译： 本发明的领域是口服药物药物产品或组合物的领域，更特别是包含一种或多种活性成分的那些类型。 本发明的目的是提供一种改进的口服药物产品，其可以以一种或多种日剂量施用，具有改进的活性成分释放（特别是活性成分），用于改善这种药物的预防和治疗功效 。 该目的通过根据本发明的多微囊口服药物形式实现，其中AP的释放通过触发释放的双重机制来控制：“时间触发”和“pH触发”。 这种药用产品包括具有活性成分释放的微胶囊，每个微胶囊含有包含活性成分的核心和一种或多种溶胀剂，以及至少一种使活性成分的修饰释放成为可能的涂层。

    Polyesterimides for use in linear and/or non-linear optics, and one method for preparing same
    36.
    发明授权
    Polyesterimides for use in linear and/or non-linear optics, and one method for preparing same 失效
    用于线性和/或非线性光学的聚酰亚胺及其制备方法

    公开(公告)号：US5811507A

    公开(公告)日：1998-09-22

    申请号：US628639

    申请日：1996-11-14

    申请人： You-Ping Chan ,  Gilles Tapolsky ,  Remi Meyrueix ,  Jean-Pierre Lecomte ,  Michael Dickens

    发明人： You-Ping Chan ,  Gilles Tapolsky ,  Remi Meyrueix ,  Jean-Pierre Lecomte ,  Michael Dickens

    IPC分类号： G02F1/01 ,  C08G63/685 ,  C08G73/16 ,  G02F1/35 ,  G02F1/355 ,  G02F1/361

    CPC分类号： G02F1/3617 ,  C08G63/6856 ,  C08G73/16

    摘要： The present invention relates to a new polyesterimide of the type containing ester repeat functional groups E=--CO--O--, imide repeat functional groups I: ##STR1## and at least one chromophore, characterized in that it contains a quantity of recurrent amide functional groups capable of ring closure to imides which is smaller than or equal to 5 mol % relative to the sum of the imide functional groups and of the amide functional groups capable of ring closure to imides, which are present, and in that the polymerization functional groups consist essentially of E functional groups. This polyesterimide is preferably free from amide functional groups capable of ring closure to imides. One of the processes for obtaining this polyesterimide constitutes another subject-matter of the invention. Such a polymer is advantageously capable of behaving like a material that is transparent and/or active in nonlinear optics. It therefore constitutes a raw material of choice for producing LO and/or NLO devices: filters, polarizers, waveguides, a modulator, directional coupler, optical flip-flop and photoconductive film.

    摘要翻译： PCT No.PCT / FR94 / 01219 Sec。 371日期：1996年11月14日 102（e）日期1996年11月14日PCT 1994年10月20日PCT PCT。 第WO95 / 11476号公报 日期：1995年04月27日本发明涉及含有酯重复官能团的类型的新的聚酯酰亚胺E = -CO-O-，酰亚胺重复官能团I：＆lt; IMAGE＆gt;和至少一种发色团，其特征在于它含有 能够闭环的酰胺官能团的量相对于酰亚胺官能团和能够闭合的酰胺官能团的总和小于或等于5摩尔％，其存在和存在于酰亚胺中 聚合官能团基本上由E官能团组成。 该聚酯酰亚胺优选不含能够闭合成酰亚胺的酰胺官能团。 获得该聚酯酰亚胺的方法之一构成本发明的另一主题。 这种聚合物有利地能够表现得像非线性光学中透明和/或有活性的材料。 因此，它构成了生产LO和/或NLO器件的首选材料：滤波器，偏振器，波导，调制器，定向耦合器，光学触发器和光电导膜。